期刊
CLINICAL AND EXPERIMENTAL DERMATOLOGY
卷 47, 期 3, 页码 573-577出版社
WILEY
DOI: 10.1111/ced.14953
关键词
-
类别
The study found that Favipiravir (FVP) may induce cutaneous adverse reactions in COVID-19 patients. Clinicians should be aware of this potential drug-related allergy and exclude it as a cause of rash during FVP treatment for COVID-19.
Favipiravir (FVP) has been used for treatment of COVID-19 in many countries. We analysed the incidence of FVP-induced cutaneous adverse reactions (CARs) in patients infected with COVID-19 who were hospitalized at Bamrasnaradura Infectious Diseases Institute, a principal centre of emerging infectious disease in Thailand, and who presented with cutaneous eruption following FVP prescription. We identified five cases of FVP-induced CARs: two patients with maculopapular rash, two with urticarial rash, and one with Stevens-Johnson syndrome. The median interval between FVP treatment and rash occurrence was 7 days and the mean duration of the rash was 5 days. This report highlights that FVP can induce CARs, particularly eruptions, in COVID-19-infected patients. Clinicians should be aware of this possible drug-related allergy, and it should be excluded as a cause of rash during FVP treatment of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据